Loading...
Recursion Pharmaceuticals, Inc.
RXRX•NASDAQ
HealthcareBiotechnology
$5.49
$0.92(20.13%)
Recursion Pharmaceuticals, Inc. (RXRX) Financial Performance & Statements
Review Recursion Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
32.00%
↑ 32.00%
Operating Income Growth
-36.83%
↓ 36.83%
Net Income Growth
-41.33%
↓ 41.33%
Operating Cash Flow Growth
-24.81%
↓ 24.81%
Operating Margin
-960.64%
↓ 960.64%
Gross Margin
-0.08%
↓ 0.08%
Net Profit Margin
-961.61%
↓ 961.61%
ROE
-74.68%
↓ 74.68%
ROIC
-49.35%
↓ 49.35%
Recursion Pharmaceuticals, Inc. (RXRX) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Recursion Pharmaceuticals, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $4.51M | $26.08M | $14.42M | $13.79M |
| Cost of Revenue | $12.79M | $12.08M | $13.10M | $14.57M |
| Gross Profit | -$8.28M | $14.003M | $1.32M | -$772000.00 |
| Gross Profit Ratio | -$1.84 | $0.54 | $0.09 | -$0.06 |
| R&D Expenses | $98.33M | $74.60M | $70.03M | $64.16M |
| SG&A Expenses | $77.19M | $37.76M | $31.83M | $31.41M |
| Operating Expenses | $175.49M | $112.36M | $101.86M | $95.57M |
| Total Costs & Expenses | $188.28M | $124.44M | $114.96M | $110.13M |
| Interest Income | $4.62M | $3.83M | $3.27M | $4.05M |
| Interest Expense | $605000.00 | $553000.00 | $394000.00 | $20000.00 |
| Depreciation & Amortization | $12.95M | $7.20M | $8.00M | $7.40M |
| EBITDA | -$165.34M | -$87.92M | -$89.67M | -$84.73M |
| EBITDA Ratio | -$36.65 | -$3.37 | -$6.42 | -$6.45 |
| Operating Income | -$183.77M | -$98.35M | -$100.54M | -$96.34M |
| Operating Income Ratio | -$40.74 | -$3.77 | -$6.97 | -$6.98 |
| Other Income/Expenses (Net) | $4.87M | $2.68M | $2.48M | $4.19M |
| Income Before Tax | -$178.90M | -$95.67M | -$98.06M | -$92.15M |
| Income Before Tax Ratio | -$39.66 | -$3.67 | -$6.80 | -$6.68 |
| Income Tax Expense | $7000.00 | $167000.00 | -$523000.00 | -$779000.00 |
| Net Income | -$178.91M | -$95.67M | -$97.54M | -$91.37M |
| Net Income Ratio | -$39.66 | -$3.67 | -$6.77 | -$6.62 |
| EPS | -$0.53 | -$0.34 | -$0.40 | -$0.39 |
| Diluted EPS | -$0.53 | -$0.34 | -$0.40 | -$0.39 |
| Weighted Avg Shares Outstanding | $336.04M | $282.58M | $242.20M | $236.02M |
| Weighted Avg Shares Outstanding (Diluted) | $336.04M | $282.58M | $242.20M | $236.02M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan